<div id="readability-page-1"><div>RNS Number : 7324G Incanthera PLC 07 November 2025 7 November 2025Incanthera plc(&#34;Incanthera&#34; the &#34;Company&#34;)Result of AGM 2025Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology announces that at its AGM held on 7 November 2025 all resolutions were duly passed.Details of the votes cast for each Resolution are as follows.<div><table><tbody><tr><td rowspan="2">Resolution</td><td rowspan="2">For</td><td rowspan="2">%</td><td rowspan="2">Against</td><td rowspan="2">%</td><td rowspan="2">Total</td><td rowspan="2">% of ISC voted</td><td rowspan="2">Withheld*</td><td></td></tr><tr><td></td></tr><tr><td>1. To receive the company's annual reports and accounts for the financial year ended 31 March 2025 together with the latest Directors' Report and the Auditors' Report of the Company</td><td>35,632,832</td><td>73.17%</td><td>13,065,834</td><td>26.83%</td><td>48,698,666</td><td>43%</td><td>138,602</td><td></td></tr><tr><td>2. To re-elect Caroline Murray, who retires under article 23.4.2 of the Company's articles of association and who, being eligible, offers herself for re-election as a Director.</td><td>48,654,900</td><td>99.64%</td><td>177,378</td><td>0.36%</td><td>48,832,278</td><td>43%</td><td>4,990</td><td></td></tr><tr><td>3. To re-elect Crowe UK LLP as auditors of the Company until the next annual general meeting of the Company and to authorise the directors to determine their remuneration.</td><td>48,813,676</td><td>100.00%</td><td>0</td><td>0.00%</td><td>48,813,676</td><td>43%</td><td>23,592</td><td></td></tr><tr><td>4. To authorise the directors to allot shares.</td><td>48,641,019</td><td>99.88%</td><td>57,647</td><td>0.12%</td><td>48,698,666</td><td>43%</td><td>138,602</td><td></td></tr><tr><td>5. To disapply the statutory pre-emption provisions.**</td><td>48,541,019</td><td>99.68%</td><td>157,647</td><td>0.32%</td><td>48,698,666</td><td>43%</td><td>138,602</td><td></td></tr></tbody></table></div> * Votes &#34;For&#34; and &#34;Against&#34; are expressed as a percentage of votes cast. Votes &#34;For&#34; include discretionary votes. A &#34;Vote withheld&#34; is not a vote in law and is therefore not counted in the calculation of the votes &#34;For&#34; or &#34;Against&#34; a resolution.** Indicates special resolutions requiring a 75% majority.While all resolutions were duly passed, Resolution 1 received over 20% of votes against it. In accordance with the QCA Corporate Governance Code, the Board confirms that it will continue to consult and engage with the relevant shareholders with respect to Resolution 1 to further understand their views.The Company would like to thank all Shareholders who returned their Proxy form and attended in person. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).The Directors of the Company accept responsibility for the content of this announcement.For further information please contact:<div><table><tbody><tr><td>Incanthera plcwww.incanthera.comTim McCarthy, Chairmantim.mccarthy@incanthera.comSimon Ward, Chief Executive Officersimon.ward@incanthera.comSuzanne Brocks, Head of Communicationssuzanne.brocks@incanthera.com</td><td>+44 (0) 7831 675747+44 (0) 7747 625506+44 (0) 7776 234600</td></tr><tr><td>Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLPJo Turner / Liam Murray / Ed Downes</td><td>+44 (0) 20 7213 0880</td></tr><tr><td>Broker: Stanford Capital Partners LtdPatrick Claridge / Bob Pountney</td><td>+44 (0) 20 3650 3650/51</td></tr></tbody></table></div>Notes to EditorsAbout Incanthera plcIncanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology, delivering treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy.Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform.The Company's current focus is Skin + CELL, Incanthera's unique luxury skincare brand in a range of dermatological applications to meet currently unmet needs in the skincare market.For more information on the Company please visit: www.incanthera.com@incantheraplcAbout Skin + CELL Skin + CELL is Incanthera's luxury skincare brand utilising, launched in August 2025. Our ground-breaking formulation and delivery expertise brings scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.www.skinandcell.comThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NEXUPGUGGUPAGCM</div></div>

Incanthera PLC announced the results of its AGM held on 7 November 2025, where all resolutions were passed. Notably, Resolution 1 received over 20% votes against it, prompting the Board to engage with shareholders for further insights. The company focuses on innovative dermatology and oncology technologies and has launched its luxury skincare brand, Skin + CELL, aimed at addressing unmet needs in the skincare market. The announcement contains inside information as per EU regulations.

REG - Incanthera PLC - Result of AGM